NET CLINICAL TRIALS IN CANADA

For an up-to-date listing of all active recruiting NET Clinical Trials please visit: Neuroendocrine Tumour Open Trials – Canada

Click on each trial to go to more information including protocol, objectives, entry criteria, investigators and locations in Canada.

Status Study Title Intervention Locations
Recruiting 68Ga-DOTA-TATE PET/CT Imaging in NETs
Diagnostic Test: 68Ga-DOTA-TATE
CHUS – Sherbrooke, Quebec, Canada
Recruiting A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
Drug: [177]Lu-DOTA-TATE
Cross Cancer Institute – Edmonton, Alberta, Canada
Recruiting 68Ga-DOTATATE PET for Management of Neuroendocrine Tumors
Diagnostic Test: 68Ga -DOTATATE PET scans
Princess Margaret Cancer Centre – Toronto, Ontario, Canada
Recruiting DOTATOC PET/CT for Imaging NET Patients
Diagnostic Test: 68Ga-DOTATOC PET/CT
Diagnostic Test: 18F-FDG PET/CT
BC Cancer – Vancouver, British Columbia, Canada
Recruiting Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors
Diagnostic Test: 18F-DOPA with furosemide
University of Alberta Hospital – Edmonton, Alberta, Canada
Recruiting Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
Drug: F18-FDG
Princess Margaret Cancer Centre – Toronto, Ontario, Canada
Recruiting Personalized PRRT of Neuroendocrine Tumors
Drug: 177Lu-Octreotate
CHU de Québec – Université Laval – Quebec City, Quebec, Canada
Recruiting A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (SORENTO)

SORENTO PATIENT BROCHURE
Drug: CAM2029
Drug: Octreotide LAR
Drug: Lanreotide ATG
London Health Sciences Centre – London, Ontario
The Ottawa Hospital General Campus – Ottawa, Ontario
Princess Margaret Cancer Centre – Toronto, Ontario
Sunnybrook Health Sciences Centre – Toronto, Ontario
BC Cancer Agency Vancouver Centre – Vancouver, BC
Recruiting A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
Drug: [68]Ga-HA-DOTATATE
Cross Cancer Institute – Edmonton, Alberta, Canada
Recruiting 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Drug: 68Ga-HA-DOTATATE
University of Alberta – Edmonton, Alberta, Canada
Recruiting Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
Diagnostic Test: 18F-FDG PET/CT
Diagnostic Test: 68Ga-DOTATOC PET/CT
BC Cancer – Vancouver, British Columbia, Canada
Recruiting 18F-DOPA II – PET Imaging Optimization
Drug: 18F-DOPA
Drug: Furosemide Injection
WC Mackenzie Health Science Centre / University of Alberta Hospital – Edmonton, Alberta, Canada
Not yet recruiting 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
Drug: 177Lu-DOTATOC
BC Cancer – Vancouver, British Columbia, Canada
Recruiting Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Drug: Lutetium [177Lu] oxodotreotide/dotatate
CHU de Québec – Université Laval – Québec, Canada
Recruiting FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for Treatment of Patients With Select Solid Tumors (FRONTIER)
Drug: [Ga-68]-PNT6555
Drug: [Lu-177]-PNT6555
University Health Network – Princess Margaret Cancer Centre – Toronto, Ontario, Canada
CHUM – Centre hospitalier de l’Université de Montréal – Montréal, Quebec, Canada
Jewish General Hospital – Montréal, Quebec, Canada

Recruiting

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Drug: 40 mg or 80 mg Paltusotine
Crinetics Study Site – Toronto, Ontario

Share This Story, Choose Your Platform!